University of Birmingham and Acticor Biotech announce MHRA approval of LIBERATE clinical study

September 7th, 2023, the University of Birmingham and Acticor Biotech announce the full regulatory approval of LIBERATE clinical study.

In 2021, the University of Birmingham and Acticor Biotech signed a partnership agreement to evaluate glenzocimab efficacy in myocardial infarction in a new clinical trial called LIBERATE. The University has received full regulatory approvals to initiate the study.

The randomized, double-blind Phase 2b LIBERATE study will recruit more than 200 patients suffering from a ST-elevation myocardial infarction and planned for a percutaneous coronary intervention. The study aims to assess the safety and the efficacy of glenzocimab 1000 mg versus placebo to reduce the myocardial infarct size at Day 90 post-treatment.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

NewsMedical /  🏆 19. in UK

United Kingdom Latest News, United Kingdom Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Boy arrested in Birmingham on suspicion of terrorism offencesThe 17-year-old remains in custody after being arrested at an address in Birmingham on Thursday.
Read more »

Government will 'do what is right' for BirminghamChancellor Jeremy Hunt says he will 'study carefully' any formal request for help by the 'bankrupt' city.
Read more »